🇺🇸

US SEC Filing Intelligence

· daily

High-Value Federal Grants ($5M+) — April 25, 2026

This digest covers 11 high-value federal grants totaling $1,160,990,335 in obligations, all civilian agency awards with 0 defense-related contracts, highlighting robust spending by DHS (Coast Guard), HHS (NIH/CMS), VA, and GSA. Dominant themes include construction for Coast Guard infrastructure recapitalization ($373.6M across L3Harris $151.9M, Whiting-Turner $137.8M, Birdon $83.9M) and federal facilities (J.E. Dunn $151.5M GSA FDA lab, Hensel Phelps $127.6M NIH), alongside IT/DevSecOps services to VA ($117.3M Veterans EZ Info) and HHS ($238.7M total Leidos and others). Highest-conviction bullish signal is multi-year construction revenue visibility for Whiting-Turner and J.E. Dunn through 2029 amid stable civilian funding. Key risk is pervasive high fixed-price execution risk across top awards, with low outlays signaling early-stage potential delays.

11 total filings
· daily

General Federal Contracts — April 25, 2026

This digest synthesizes 11 civilian federal contracts totaling $1,160,990,335 in obligations (0/11 defense-related), highlighting a civilian infrastructure and IT services theme dominated by DHS Coast Guard ($457.4M across four contracts) and HHS ($365.8M across four contracts). Highest-conviction bullish signals emerge from large construction awards to J.E. Dunn Construction Company ($151.5M GSA) and Whiting-Turner Contracting Company ($137.8M DHS Coast Guard), signaling multi-year revenue visibility through 2029 amid stable civilian agency spending. Leidos, Inc. captures two HHS IT contracts worth $158.7M combined, bolstering its civilian health IT exposure. Key risk is high fixed-price execution risk across top materiality contracts like L3Harris ($151.9M DHS) and Hensel Phelps ($127.6M HHS), with low outlays on newer awards vulnerable to spending delays.

11 total filings
· daily

Biotech Small-Cap Approvals — April 24, 2026

The FDA granted 4 'Other' approvals in the biotech small-cap stream for the period April 24 to April 24, 2026, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 4 others, all carrying neutral signals (strength and materiality 5/10). These include ANTHEA PHARMA's BUPIVACAINE HYDROCHLORIDE, ALKEM LABORATORIES LIMITED's TOLVAPTAN, LAURUS's VALSARTAN, and SANDOZ's ENZALUTAMIDE, each described as biosimilar FDA approvals despite the mix categorization. No dominant therapeutic area theme emerges, with products spanning anesthesia (BUPIVACAINE HYDROCHLORIDE), nephrology/cardiovascular (TOLVAPTAN, VALSARTAN), and oncology (ENZALUTAMIDE). The highest-conviction signal is SANDOZ's ENZALUTAMIDE approval, a neutral event implying modest commercial entry into a mature market with NOT_DISCLOSED peak sales and exclusivity. Key risk/watch item is the complete lack of disclosed commercial data (peak sales, exclusivity, pricing power, market position), raising execution uncertainty for these small-cap entrants.

4 total filings
· daily

Big Pharma Approvals — April 24, 2026

This week's Big Pharma approvals include 0 NMEs, 0 biosimilars, 0 label expansions, and 2 other approvals, delivering 2 bullish signals with no bearish or neutral outcomes. Regeneron Pharmaceuticals' label expansion for Dupilumab (Dupixent) provides a moderate bullish catalyst (strength 5/10, materiality 5/10), reinforcing its established franchise. The highest-conviction signal is Merck Sharp and Dohme LLC's NME approval for Doravirine and Islatravir (Idvynso™) (strength 8/10, materiality 8/10), highlighting strong pipeline execution despite 'other' categorization. No dominant therapeutic area theme emerges, as approvals span distinct profiles. Key risk/watch item: Lack of disclosed peak sales, exclusivity, pricing, and market position data warrants monitoring commercial traction post-approval.

2 total filings
· daily

New Drug Approvals (Original) — April 24, 2026

The FDA granted 5 approvals classified as Other during this period (0 NMEs, 0 biosimilars, 0 label expansions per official mix), consisting of 4 biosimilar approvals and 1 NME. These span diverse areas including anesthesia (BUPIVACAINE HYDROCHLORIDE), nephrology/cardiovascular (TOLVAPTAN, VALSARTAN), oncology (ENZALUTAMIDE), and HIV (DORAVIRINE AND ISLATRAVIR), with no dominant therapeutic area clustering. The highest-conviction bullish signal is MERCK SHARP AND DOHME LLC's NME approval for DORAVIRINE AND ISLATRAVIR (IDVYNSOTM), marking a first-in-class HIV therapy with 5-year NCE exclusivity and strong pipeline execution signal for Merck. Biosimilar approvals for ANTHEA PHARMA, ALKEM LABORATORIES LIMITED, LAURUS, and SANDOZ are neutral overall but carry dual implications: upside for entrants, downside risks for originators. Key risk/watch item: competitive revenue erosion for originators of these biosimilars (30-60% potential over 2-3 years).

5 total filings
· daily

Federal Construction & Infrastructure Contracts — April 24, 2026

A single $129,150,000 firm fixed-price contract was awarded to RECORD STEEL AND CONSTRUCTION, INC. by the Department of the Interior's National Park Service, representing 100% civilian exposure with zero defense-related obligations. The award supports rehabilitation of Canyon Village wastewater treatment systems in Yellowstone National Park under full and open competition, signaling sustained Interior/NPS spending on facilities maintenance amid a neutral overall signal (avg strength 3.0/10). Highest-conviction signal is the potential future revenue stream estimated at $71M annually over the 1.83-year performance period from 2026-04-22 to 2028-02-14, with no funds outlayed yet ($0). Key risk is high pricing risk inherent to the firm fixed-price structure; watch total outlayed progress and performance milestones toward the 2028-02-14 end date.

1 total filings
· daily

New Federal Contractors — April 24, 2026

A single civilian contract totaling $129,150,000 was awarded with zero defense exposure during April 24, 2026. The Department of the Interior's National Park Service selected RECORD STEEL AND CONSTRUCTION, INC. via full and open competition for a firm-fixed price rehabilitation of Canyon Village wastewater treatment systems in Yellowstone National Park, spanning 2026-04-22 to 2028-02-14. The neutral signal (3/10 strength, 2/10 materiality) reflects a future revenue stream estimated at $71M annually over 1.83 years but no immediate outlays ($0). Dominant theme is sustained NPS facilities maintenance spending. Highest-conviction signal is medium-term civilian infrastructure growth for non-defense construction. Key risk is high pricing execution on the firm-fixed price structure; watch total outlayed progress.

1 total filings
· daily

Significant Contract Modifications ($10M+) — April 24, 2026

This period features a single significant contract modification totaling $129,150,000 in obligations, with a 0/1 defense-related split indicating fully civilian exposure via the Department of the Interior's National Park Service. RECORD STEEL AND CONSTRUCTION, INC. received a $129,150,000 firm fixed price contract under full and open competition for rehabilitating Canyon Village wastewater treatment systems in Yellowstone National Park, WY, spanning 2026-04-22 to 2028-02-14. The dominant agency theme is sustained NPS spending on facilities maintenance and infrastructure rehabilitation (NAICS 237110, PSC Y1ND). The highest-conviction signal is neutral (strength 3/10, materiality 2/10), highlighting a future revenue stream estimated at $71M annually with $0 outlayed to date. A key risk is high pricing risk inherent to the firm fixed price structure, with no immediate revenue recognition.

1 total filings
· daily

Contract Deobligations Alert — April 24, 2026

This digest covers one civilian government contract totaling $129,150,000 in obligations, with a 0/1 defense-related split, highlighting Department of the Interior/National Park Service spending on infrastructure rehabilitation. RECORD STEEL AND CONSTRUCTION, INC. received a $129,150,000 firm fixed price award under full and open competition for Canyon Village wastewater treatment systems rehabilitation in Yellowstone National Park, WY, spanning 2026-04-22 to 2028-02-14. The neutral signal (strength 3/10, materiality 2/10) points to a future revenue stream estimated at $71M annually with $0 outlayed to date. The highest-conviction signal is low-confidence medium-term civilian infrastructure growth for the contractor. A key risk is high pricing risk inherent to the firm fixed price structure, with a watch item on total outlayed progress from $0.

1 total filings
· daily

Contract Option Exercises — April 24, 2026

A single $129,150,000 firm fixed price contract was exercised by the Department of the Interior's National Park Service to RECORD STEEL AND CONSTRUCTION, INC. for rehabilitating Canyon Village wastewater treatment systems in Yellowstone National Park, representing 100% civilian spending with 0 defense-related obligations. This neutral signal (strength 3/10, materiality 2/10) underscores sustained NPS facilities maintenance in water/sewer infrastructure (NAICS 237110, PSC Y1ND), with an estimated $71M annual revenue over the 1.83-year performance period from 2026-04-22 to 2028-02-14. No funds have been outlayed ($0 total), signaling future cash flows for this Boise, ID-based non-small business but no immediate revenue recognition. Highest-conviction signal is neutral future revenue potential amid full and open competition. Key risk is high pricing risk on the firm fixed price structure; watch total outlayed progress from $0.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 24, 2026

This period's sole contract totals $129,150,000 in obligations, representing 100% civilian exposure with 0/1 defense-related awards from the Department of the Interior's National Park Service. RECORD STEEL AND CONSTRUCTION, INC. was awarded a firm fixed-price contract for Canyon Village wastewater treatment rehabilitation in Yellowstone National Park, WY, under full and open competition, signaling sustained NPS facilities maintenance spending in water/sewer infrastructure (NAICS 237110, PSC Y1ND). The highest-conviction signal is neutral (strength 3/10, materiality 2/10) due to no immediate outlays ($0 total) and future revenue potential estimated at $71M annually over the 1.83-year performance period from 2026-04-22 to 2028-02-14. A key risk is high pricing risk inherent to the firm fixed-price structure; watch total outlayed progress from $0 and performance milestones toward the 2028-02-14 end date.

1 total filings
· daily

High-Value Federal Grants ($5M+) — April 24, 2026

A single $129,150,000 firm fixed price contract awarded by the Department of the Interior's National Park Service to RECORD STEEL AND CONSTRUCTION, INC. represents the entirety of high-value federal grants analyzed for April 24, 2026, with a 0/1 defense-related split indicating purely civilian exposure. The award funds rehabilitation of Canyon Village wastewater treatment systems in Yellowstone National Park, WY, under full and open competition, signaling sustained NPS spending on infrastructure maintenance but with neutral investment conviction (avg signal strength 3.0/10). No funds have been outlayed yet ($0 total), pointing to future revenue potential estimated at $71M annually over the 1.83-year performance period from 2026-04-22 to 2028-02-14. Highest-conviction signal is neutral future cash flows for this private Boise, ID-based non-small business contractor. Key risk is high pricing risk inherent to the firm fixed price structure, with watch item on total outlayed progress from $0.

1 total filings
· daily

General Federal Contracts — April 24, 2026

A single civilian contract totaling $129,150,000 was awarded by the Department of the Interior's National Park Service to RECORD STEEL AND CONSTRUCTION, INC., representing 0% defense exposure in this period's aggregate. The firm fixed-price award for Canyon Village wastewater treatment rehabilitation in Yellowstone National Park signals neutral investment potential with low strength (3/10) and materiality (2/10). Dominant theme is sustained NPS spending on national park infrastructure maintenance in water/sewer construction (NAICS 237110, PSC Y1ND). Highest-conviction signal is deferred revenue recognition potential, with $0 outlayed across the $129M obligation indicating future cash flows over 1.83 years to 2028-02-14. Key risk is high pricing risk inherent to the firm fixed-price structure; watch total outlayed progress from $0.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 24, 2026

Across 27 filings in the USA S&P 500 Technology intelligence stream, proxy season dominates with 15+ DEF 14A/DEFA14A disclosures signaling upcoming AGMs in May-June 2026 as key catalysts for governance votes, equity plan expansions, and say-on-pay approvals (e.g., Acadia May 29, Block June 16). Q1 2026 financials show stark divergence: Texas Instruments (TXN) delivered blowout growth with revenue +18.6% YoY to $4.8B, net income +31% to $1.5B, and op cash flow +79% to $1.5B, contrasting Charter Communications' -1% YoY revenue decline to $13.6B amid video revenue -9.1%. Institutional 13F filings (Muzinich, Semus, United Community Bank, Squire) reveal persistent conviction in mega-cap tech leaders like AAPL ($34M-$4B positions), NVDA ($7.5M+), MSFT, AMZN, underscoring portfolio concentration in growth tech. Capital allocation remains shareholder-friendly with TXN's $1.3B Q1 dividends, FHLB's $75M special dividend, Genco's record $0.50/share, and Charter's buybacks boosting EPS +7.9% despite NI drop. Mixed sentiment prevails (9 mixed, 13 neutral, 3 positive), with no major insider selling but positive exec comp beats (Immunome bonuses 145-150% of target). Forward catalysts include Altimmune's Phase 3 MASH trial funding from $211M raise and Genco's proxy battle. Overall, tech sector shows resilient institutional demand and semi strength amid broader mixed trends, favoring longs in outperformers like TXN.

13 high priority 14 medium 27 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 24, 2026

Across 33 filings from NASDAQ-100 related entities, proxy statements dominate (18/33) signaling peak annual meeting season in May-June 2026, with positive executive comp and achievements in biotech/tech (e.g., Immunome exceeded targets 145-150%, Alphabet Gemini launch). Q1 2026 financials show semis rebounding (Intel rev +7.2% YoY to $13.6B, TI +18.6% to $4.8B) amid CHIPS incentives, but mixed elsewhere: telecom softness (Charter rev -1% YoY), coal disruptions (Alpha Met Q1 loss $11M), and sharp declines (ILAG rev -40.1% YoY). Capital returns strong (Comcast $11.7B buybacks/divs reducing shares 5%, TI $1.29B divs), with biotech funding wins (Altimmune $211M for Phase 3 MASH trial). Portfolio trends: Revenue growth avg +10% YoY in reporting cos (5/7), but losses prevalent (Intel $3.7B net loss, Blue Moon $38.8M); positive sentiment 12/33, mixed 10/33. Key implications: Watch proxy votes for equity plan approvals adding shares (Alphabet 200M Class C), semis for foundry ramps, biotechs for catalysts.

16 high priority 17 medium 33 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 24, 2026

The 50 filings in the USA S&P 500 Financials intelligence stream reveal a mix of proxy statements (20+ filings, neutral sentiment) for June 2026 AGMs focusing on director elections, auditor ratifications, and exec comp approvals, alongside 20+ 13F-HR snapshots from asset managers showing heavy tech overweight (Apple, NVDA, AMZN top across portfolios) but notable financials exposure (Visa $134M top at Ninety One, JPM $32M at Alley, BDCs like Ares $40M at Muzinich). Period-over-period trends highlight strong revenue growth in financials/fintech (UP Fintech +56.3% YoY to $612M, First American +16.2% YoY to $1.84B) averaging +30% YoY across growth reporters, but mixed profitability (Flagstar Q1 NI turnaround from -$100M YoY loss to +$21M, yet NII -5% QoQ). Margin compression evident in non-financials (Gravity gross margin -370bps to 35%, Medicure gross profit -10% despite +32% rev), with capital allocation favoring returns (First Am $33.5M buybacks + $56M dividends Q1, News Corp $1B ongoing buyback). No widespread insider trading patterns, but regulatory risks loom (UP Fintech delisting threat). Implications: Bullish on recovering banks/insurers, watch proxy votes and fintech regs for near-term catalysts.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 24, 2026

Across 50 SEC filings for the USA S&P 500 Consumer Staples intelligence stream (despite broader coverage including tech/industrials), key themes include mixed Q1/FY26 earnings with revenue growth averaging +8% YoY in reporters like Procter & Gamble (+7% Q3 sales to $21.2B, organic +3%), Philip Morris (+9.1% to $10.1B), Intel (+7.2%), and Sibanye Stillwater (+15.6%), but persistent margin compression (e.g., P&G core gross -100bps, op -80bps) and earnings volatility from one-offs/restructuring. Proxy season dominates with 20+ AGMs clustered in June 2026, featuring director elections, say-on-pay, equity plan expansions, and governance tweaks like bylaws (JPM, Kontoor). 13F-HR filings (12 total) reveal institutional portfolios heavily tilted to tech megacaps (e.g., Chicago Capital $187M Alphabet, Sumitomo $592M Apple), signaling rotation away from staples amid neutral sentiment. Capital allocation emphasizes dividends (PMI +9% to $1.47/share, Sibanye 131cps) and buybacks (Charter EPS +7.9% via repurchases), with forward catalysts like Honeywell Aerospace spin (3Q26) and Elmet IPO ($120M proceeds). Portfolio-level trends show 5/10 earnings reporters with YoY rev growth >7% but 7/10 with op margin declines avg -50bps, highlighting cost/tariff pressures; actionable now: favor staples with volume growth (P&G Beauty +7%) over volume decliners.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 24, 2026

Across 50 SEC filings from April 24, 2026, primarily 13F-HR holdings reports (25+), proxy statements (10+), and quarterly/annual financials (10+), overarching themes include peak proxy season with strong shareholder support in AGMs, institutional portfolios overwhelmingly tilted to tech/AI giants (Alphabet, Nvidia, Apple topping 80% of 13Fs), and mixed financial performance in reporters with average revenue growth +8.4% YoY across 12 firms (e.g., Sibanye +15.6%, Philip Morris +9.1%) but profitability challenges (5/12 saw net income declines, avg -5.2%). Industrials-relevant signals shine: Trane Technologies expands $1.5B credit facility signaling liquidity for growth; AITX secures construction-site AI orders; Defense Tech cash burn persists. M&A in Peoples Bancorp offers accretion potential spilling into sector stability; urban-gro defaults highlight credit risks. Portfolio-level: No insider trading patterns (absent in filings), capital allocation favors dividends (Sibanye 131 cps, PMI +9% div), with upcoming AGMs as catalysts for equity plan approvals and comp votes.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 24, 2026

Across 19 filings in the S&P 500 Energy stream, energy services and midstream firms show mixed Q1 2026 results: revenues grew modestly (SLB +3% YoY, Baker Hughes +2.5% YoY, Kinder Morgan +14% YoY) while Halliburton dipped -0.3% YoY, but net income surged dramatically (Baker +131% YoY to $930M, Halliburton +128.6% YoY to $464M, Kinder +36% YoY to $976M) driven by one-time gains and absent impairments. Devon Energy's merger with Coterra advances amid lawsuits, with supplemental DCF fairness opinions valuing Devon at $37.50-$54.97/share (vs $39.45 close) and meetings set for May 4, 2026. Capital allocation remains shareholder-friendly with SLB's $0.295/share dividend (payable July 9), Kinder's $654M dividends paid, and Baker's cash ballooning to $14.8B post-debt issuance. Non-energy filings (13Fs, REITs, tech) reveal neutral institutional positioning in tech/banks/ETFs with no energy tilt, while SLB announces M&A (OneSubsea/Envirex H1 2026, S&P software H2 2026). Portfolio-level trends indicate improving profitability (avg +98% YoY NI across core energy filers) despite sequential declines (SLB rev -11% QoQ), signaling resilience amid Middle East disruptions but vulnerability to one-offs. Key implication: tactical opportunities in merger arb and services recovery, watch May catalysts.

5 high priority 14 medium 19 total filings
· daily

US Material Events SEC 8-K Filings — April 24, 2026

Across 50 SEC 8-K filings from April 24, 2026, the dominant theme is extensive corporate governance evolution, with over 25 instances of board appointments, resignations, and C-level changes (e.g., Wheels Up adding Delta CFO designee, Intel CAO resignation), signaling strategic refreshes and partnerships amid transformation efforts. Financing activities dominate positively, including 12 credit facility expansions/refinancings (e.g., Trane Technologies $1.5B new revolver to 2031, PDF Solutions +$30M to $70M total), equity offerings (Altimmune $211M net for Phase 3 trials, Elmet IPO $120M gross), and securitizations (Consumer Portfolio $514M largest-ever), enhancing liquidity without broad debt distress. M&A and asset deals show opportunistic growth (Bio Essence $3.5M AI platform stock deal, ModuLink ASA Robotics with 213% YoY revenue, Peoples Bancorp 2.10x stock + $8 cash merger), while annual meetings (#2,4,20,24,44) passed equity plans and comp votes with 90%+ support on average, indicating shareholder alignment. Risks cluster in small caps (SHF Nasdaq notice to Oct 2026, Spire $71.8M CAD contract termination, Splash litigation/disputes), but no widespread margin compression or YoY declines beyond isolated cases; positive sentiments in 60%+ filings suggest portfolio resilience. Key implication: liquidity bolstering positions firms for growth catalysts like Phase 3 trials and regulatory approvals, favoring long positions in transforming industrials/tech/biotech over microcaps.

50 high priority 50 total filings